SANTA CLARA, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, which is being held from Monday, January 8 to Thursday, January 11, 2024, in San Francisco, CA.

Shockwave management is scheduled for a live presentation on Wednesday, January 10, 2024, at 7:30 a.m. Pacific Time. Interested parties may access a live and archived webcast of the event on the "Investors" section of the company’s website at: https://ir.shockwavemedical.com.

About Shockwave Medical, Inc.
Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com and www.neovasc.com.

Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com

Investor Contact:
Debbie Kaster
investors@shockwavemedical.com